123 related articles for article (PubMed ID: 30279110)
1. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
Lam VK; Tran HT; Banks KC; Lanman RB; Rinsurongkawong W; Peled N; Lewis J; Lee JJ; Roth J; Roarty EB; Swisher S; Talasaz A; Futreal PA; Papadimitrakopoulou V; Heymach JV; Zhang J
Clin Lung Cancer; 2019 Jan; 20(1):30-36.e3. PubMed ID: 30279110
[TBL] [Abstract][Full Text] [Related]
2. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung.
Alidousty C; Becker A; Binot E; Hillmer AM; Merkelbach-Bruse S; Budde B; Bäßmann I; Rappl G; Wolf J; Eich ML; Noh KW; Buettner R; Schultheis AM
Gene; 2024 Feb; 895():148018. PubMed ID: 37981082
[TBL] [Abstract][Full Text] [Related]
3. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Banks KC; Lanman RB; Talasaz A; Parker BA; Kurzrock R
Oncotarget; 2016 Mar; 7(9):9707-17. PubMed ID: 26848768
[TBL] [Abstract][Full Text] [Related]
4. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
[TBL] [Abstract][Full Text] [Related]
5. Precision medicine and actionable alterations in lung cancer: A single institution experience.
Mambetsariev I; Wang Y; Chen C; Nadaf S; Pharaon R; Fricke J; Amanam I; Amini A; Bild A; Chu P; Erhunmwunsee L; Kim J; Munu J; Pillai R; Raz D; Sampath S; Vora L; Qiu F; Smith L; Batra SK; Massarelli E; Koczywas M; Reckamp K; Salgia R
PLoS One; 2020; 15(2):e0228188. PubMed ID: 32045431
[TBL] [Abstract][Full Text] [Related]
6. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
[TBL] [Abstract][Full Text] [Related]
7. DNA-PK-Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance.
Wang H; Zhang Y; Tian Y; Yang W; Wang Y; Hou H; Pan H; Pei S; Zhu H; Gu Z; Zhang Y; Dai D; Chen W; Zheng M; Luo Q; Xiao Y; Huang J
Cancer Res; 2024 Mar; 84(5):688-702. PubMed ID: 38199791
[TBL] [Abstract][Full Text] [Related]
8. KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.
Pan Y; Han H; Hu H; Wang H; Song Y; Hao Y; Tong X; Patel AS; Misirlioglu S; Tang S; Huang HY; Geng K; Chen T; Karatza A; Sherman F; Labbe KE; Yang F; Chafitz A; Peng C; Guo C; Moreira AL; Velcheti V; Lau SCM; Sui P; Chen H; Diehl JA; Rustgi AK; Bass AJ; Poirier JT; Zhang X; Ji H; Zhang H; Wong KK
Cancer Cell; 2023 Jan; 41(1):88-105.e8. PubMed ID: 36525973
[TBL] [Abstract][Full Text] [Related]
9. Detection of clinically relevant epidermal growth factor receptor pathway mutations in circulating cell-free tumor DNA using next generation sequencing in squamous cell carcinoma lung.
Govind KB; Koppaka D; Dasappa L; Jacob LA; C Babu SM; Lokesh NK; Haleshappa RA; Rajeev LK; Saldanha SC; Abhishek A; Asati V; Chethan R; Ramprasad VL
South Asian J Cancer; 2019; 8(4):247-249. PubMed ID: 31807490
[TBL] [Abstract][Full Text] [Related]
10. Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort.
Bruno R; Poma AM; Panozzi M; Lenzini A; Elia G; Zirafa CC; Aprile V; Ambrogi MC; Baldini E; Lucchi M; Melfi F; Chella A; Sbrana A; Alì G
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611088
[TBL] [Abstract][Full Text] [Related]
11. The 12p13.33/RAD52 locus and genetic susceptibility to squamous cell cancers of upper aerodigestive tract.
Delahaye-Sourdeix M; Oliver J; Timofeeva MN; Gaborieau V; Johansson M; Chabrier A; Wozniak MB; Brenner DR; Vallée MP; Anantharaman D; Lagiou P; Holcátová I; Richiardi L; Kjaerheim K; Agudo A; Castellsagué X; Macfarlane TV; Barzan L; Canova C; Thakker NS; Conway DI; Znaor A; Healy CM; Ahrens W; Zaridze D; Szeszenia-Dabrowska N; Lissowska J; Fabianova E; Mates IN; Bencko V; Foretova L; Janout V; Curado MP; Koifman S; Menezes A; Wünsch-Filho V; Eluf-Neto J; Boffetta P; Garrote LF; Serraino D; Lener M; Jaworowska E; Lubiński J; Boccia S; Rajkumar T; Samant TA; Mahimkar MB; Matsuo K; Franceschi S; Byrnes G; Brennan P; McKay JD
PLoS One; 2015; 10(3):e0117639. PubMed ID: 25793373
[TBL] [Abstract][Full Text] [Related]
12. c-Rel is a Novel Oncogene in Lung Squamous Cell Carcinoma Regulating Cell Proliferation and Migration.
Luo R; Liu Q; Hu Z; Dai W; Huang S; Xie J; Wei S; Lin C
J Cancer; 2024; 15(8):2329-2339. PubMed ID: 38495491
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing in dermatology.
King AD; Deirawan H; Klein PA; Dasgeb B; Dumur CI; Mehregan DR
Front Med (Lausanne); 2023; 10():1218404. PubMed ID: 37841001
[TBL] [Abstract][Full Text] [Related]
14. Author Correction: Pan-cancer image-based detection of clinically actionable genetic alterations.
Kather JN; Heij LR; Grabsch HI; Loeffler C; Echle A; Muti HS; Krause J; Niehues JM; Sommer KAJ; Bankhead P; Kooreman LFS; Schulte JJ; Cipriani NA; Buelow RD; Boor P; Ortiz-Brüchle N; Hanby AM; Speirs V; Kochanny S; Patnaik A; Srisuwananukorn A; Brenner H; Hoffmeister M; van den Brandt PA; Jäger D; Trautwein C; Pearson AT; Luedde T
Nat Cancer; 2020 Nov; 1(11):1129. PubMed ID: 35122072
[No Abstract] [Full Text] [Related]
15. Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map?
Berger NA
Transl Cancer Res; 2016 Aug; 5(Suppl 2):S243-S247. PubMed ID: 27656419
[No Abstract] [Full Text] [Related]
16. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD
Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
[TBL] [Abstract][Full Text] [Related]
17. Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
Iwama E; Sakai K; Azuma K; Harada D; Nosaki K; Hotta K; Nishio M; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Cancer Sci; 2018 Dec; 109(12):3921-3933. PubMed ID: 30289575
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Aggarwal C; Thompson JC; Black TA; Katz SI; Fan R; Yee SS; Chien AL; Evans TL; Bauml JM; Alley EW; Ciunci CA; Berman AT; Cohen RB; Lieberman DB; Majmundar KS; Savitch SL; Morrissette JJD; Hwang WT; Elenitoba-Johnson KSJ; Langer CJ; Carpenter EL
JAMA Oncol; 2019 Feb; 5(2):173-180. PubMed ID: 30325992
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
[TBL] [Abstract][Full Text] [Related]
20. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.
Slavin TP; Banks KC; Chudova D; Oxnard GR; Odegaard JI; Nagy RJ; Tsang KWK; Neuhausen SL; Gray SW; Cristofanilli M; Rodriguez AA; Bardia A; Leyland-Jones B; Janicek MF; Lilly M; Sonpavde G; Lee CE; Lanman RB; Meric-Bernstam F; Kurzrock R; Weitzel JN
J Clin Oncol; 2018 Oct; 36(35):JCO1800328. PubMed ID: 30339520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
